BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study
Funding to support lead candidate targeting FAP and pipeline expansion
Updated Date: Tue, 01 Jul 2025 00:00:00 EDT
Updated Date: Tue, 01 Jul 2025 00:00:00 EDT
Updated Date: Tue, 01 Jul 2025 00:00:00 EDT
Updated Date: Tue, 01 Jul 2025 00:00:00 EDT
bmj;390/jul08_1/r1377/FAF1faBernard was a lifelong Mancunian and the first member of his family to attend university. His enthusiasm and […]
Recognition that people with lived experience of disease should be equal partners in decision making about health policy […]
New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients
Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas